Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques
What it found
No result yet.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
Différence de fréquence haplotypique entre répondeurs et non répondeurs.
Who could take part
MS (type not specified)
Inclusion: - Les patients devront avoir une sclérose en plaques rémittente-récurrente définie selon les critères de McDonald32 : Exclusion: - Patients présentant une forme progressive de SEP
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Identifier parmi les marqueurs génétiques (Single Nucleotide polymorphism, SNP) du gène ITGA4, celui ou ceux, qui sont associés à la non évolution des patients 2 ans après l’introduction du Natalizumab dans le traitement de la sclérose en plaques.
Papers
Loading reviews and guidelines…
Related trials
- Natalizumab and Chronic Inflammation
Phase 4 · Stopped early
Stopped early
- Analysis of MS Patients Who Have Had Greater Than 60 Infu…
Status unknown
No result found
- TOPIK Study: A Study to Report Progressive Multifocal Leu…
Completed
No result found
- Tysabri Observational Cohort Study - Multiple Sclerosis (…
Completed
No result found
- Personalised Dosing of Natalizumab in Multiple Sclerosis (The PDNMS trial)
Phase 4 · Ongoing
- Safety and Efficacy in Pediatric MS Patients Prescribed T…
Completed
No result found
History
Started
Mar 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error